AVB 114
Alternative Names: Autologous mesenchymal stromal cell coated fistula plug - Avobis Bio; AVB-114; MSC-AFPLatest Information Update: 25 Jul 2024
At a glance
- Originator Mayo Clinic; W. L. Gore & Associates
- Developer Avobis Bio; Mayo Clinic
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Rectal fistula
Most Recent Events
- 19 Jul 2024 Avobis Bio initiates an EAP-STOMP2 expanded-access programme for Rectal fistula in USA (Parenteral) (NCT06509828)
- 28 Dec 2022 No recent reports of development identified for phase-I development in Rectal-fistula(In adolescents, In children, Treatment-experienced) in USA (Parenteral)
- 01 Dec 2021 Phase-II clinical trials in Rectal fistula (Treatment-experienced) in USA (Parenteral) (NCT04847739)